GlassScriptPhysician profile
Richard M Rotnicki
NPI 1427062850
$4,458.77
in general payments reported to CMS, 2019-2025
28 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $321 · 2021: $223 · 2022: $527 · 2023: $686 · 2024: $578 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,052.27 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Regeneron Healthcare Solutions, INC. | $537.76 | 2023-2025 | Dupixent |
| Gi Supply, INC. | $178.76 | 2021 | |
| Janssen Biotech, INC. | $173.75 | 2019-2025 | Tremfya |
| Enterra Medical, INC. | $161.53 | 2023 | |
| Medical Device Business Services, INC. | $148.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.55 | 2019-2020 | |
| Ethicon US, LLC | $122.21 | 2019 | |
| Madrigal Pharmaceuticals | $121.36 | 2024 | Rezdiffra |
| Pfizer INC. | $121.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.69 | 2019 | |
| Janssen Scientific Affairs, LLC | $90.13 | 2019 | |
| Endogastric Solutions, INC | $68.96 | 2020 | |
| Gilead Sciences, INC. | $67.14 | 2019-2020 | |
| Romark Laboratories, Lc | $55.92 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $49.42 | 2022-2023 | Ibsrela |
| Braintree Laboratories, INC. | $48.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.01 | 2019 | |
| Mauna Kea Technologies, INC. | $38.11 | 2019-2021 | |
| Ucb, INC. | $23.37 | 2019 | |
| Boston Scientific Corporation | $21.98 | 2025 | Orcapod |
| Daiichi Sankyo INC. | $18.64 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.20 | 2024 | |
| Merck Sharp & Dohme LLC | $17.20 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.46 | 2019 | |
| Shire North American Group INC | $14.71 | 2019 | |
| Shionogi INC | $14.60 | 2019 | |
| Allergan, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rotnicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.